A5060155830- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Hormonal Regulation and Hypertension
- Advanced Radiotherapy Techniques
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Reproductive Biology and Fertility
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Management of metastatic bone disease
- Meta-analysis and systematic reviews
- Prostate Cancer Diagnosis and Treatment
- Cancer-related cognitive impairment studies
- Delphi Technique in Research
- Medical Imaging and Pathology Studies
- Meningioma and schwannoma management
- Patient Satisfaction in Healthcare
- Cancer Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Heterotopic Ossification and Related Conditions
- Palliative Care and End-of-Life Issues
- Neuroendocrine Tumor Research Advances
King's College London
2020-2021
University Hospitals Plymouth NHS Trust
2020-2021
Bayer (United Kingdom)
2021
Kings Health Partners
2020
Guy's Hospital
2020
Air Squared (United States)
2007
Centre Hospitalier Universitaire de Sherbrooke
2005
Montreal General Hospital
2005
Jewish General Hospital
2005
The University of Texas Southwestern Medical Center
2005
Promising results from new approaches such as radiosurgery or stereotactic surgery of brain metastases have recently been reported. Are these due to the therapy alone can be attributed in part patient selection? An analysis tumor/patient characteristics and treatment variables previous Radiation Therapy Oncology Group (RTOG) studies was considered necessary fully evaluate benefit interventions.The database included 1200 patients three consecutive RTOG trials conducted between 1979 1993,...
Background : Regionally advanced, surgically unresectable non-small-cell lung cancer represents a disease with an extremely poor prognosis. External-beam irradiation to the primary tumor and regional lymphatics is generally accepted as standard therapy. The use of more aggressive radiation regimens addition cytotoxic chemotherapy radiotherapy have yielded conflicting results. Recently, however, results from clinical trials using innovative delivery techniques or before indicated that...
This phase II noncomparative randomized trial was conducted to determine the optimal sequencing and integration of paclitaxel/carboplatin with standard daily thoracic radiation therapy (TRT), in patients locally advanced unresected stage III non-small-cell lung cancer (NSCLC). Survival data were compared historical sequential chemoradiotherapy from Radiation Therapy Oncology Group.Patients stages IIIA IIIB NSCLC, Karnofsky performance status > or = 70% weight loss < 10%, received two cycles...
PURPOSE Patients with locally advanced inoperable non-small-cell lung cancer (NSCLC) have a poor clinical outcome. We conducted prospective study to evaluate the merit of chemotherapy administered concurrently hyperfractionated thoracic radiation therapy. PATIENTS AND METHODS Seventy-nine patients NSCLC were enrolled onto multicenter phase II trial concurrent chemoradiation Treatment consisted two cycles oral etoposide 100 mg/d (50 if body-surface area [BSA] < 1.70 m2), intravenous...
To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves quality life and survival in patients with primary breast cancer brain metastases when used as adjunct to whole-brain radiation therapy (WBRT).Patients from were randomly assigned receive WBRT either efaproxiral or no efaproxiral. The endpoint for this analysis was quality-adjusted survival. Quality assessed prior initiation periodically follow-up using the Spitzer Life Index (SQLI).A subgroup 106 eligible...
Encouraging results of several clinical trials utilizing combination chemotherapy and irradiation in unresectable non-small-cell lung cancer have been reported. A recent report from a cooperative group study suggested that preirradiation vinblastine cisplatin improved survival over alone. In an attempt to enhance the possible effectiveness irradiation, Radiation Therapy Oncology Group embarked on Phase II trial (5 mg/m2 weekly x 5) (100 mg/m2) days 1 29 prior 50, 71, 92 during irradiation....
Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases tissue pO2. We conducted a phase II multicenter study that assessed the efficacy safety of efaproxiral when administered with thoracic radiation therapy (TRT), following induction chemotherapy, for treatment locally advanced non-small-cell lung cancer (NSCLC).Fifty-one patients NSCLC were enrolled at 13 sites. Treatment comprised two cycles paclitaxel (225 mg/m2) carboplatin (area under...
A hyperfractionated radiation therapy (HFX RT) trial (1.2 Gy twice daily, b.i.d.) (HFX) for non-small cell lung cancer (NSCLC) showed that 69.6 resulted in better survival than did lower total doses (Radiation Therapy Oncology Group, RTOG 83-11) and cisplatin concurrent with irradiation improved local control over RT alone 91-06). Concurrent combination chemotherapy HFX could improve both systemic control. In a phase II (RTOG 91-06) inoperable NSCLC, two cycles of PE were used [cisplatin 50...
Abstract Background The option of semen cryopreservation following a diagnosis testicular cancer shows variable uptake with the to cryopreserve before surgery often dependent on preference treating clinician and fertility laboratory resources available. Objectives To assess whether introduction patient‐centric pathway for managing suspected increases impact this surgical waiting times. Materials methods A multicentre retrospective analysis patients treated as part was conducted at two...